Rapid weight loss from GLP-1 receptor agonists often strips away lean mass alongside fat. Two peptides, IGF-1 LR3 and Hexarelin, are frequently discussed as potential countermeasures, but their mechanisms differ sharply. IGF-1 LR3 is a long-acting analogue of insulin-like growth factor-1 that directly activates the IGF-1 receptor, promoting protein synthesis and inhibiting protein breakdown. Hexarelin is a growth hormone secretagogue that stimulates pituitary GH release, raising systemic IGF-1 indirectly. The question is which approach better preserves muscle during a pharmacologically driven caloric deficit.
A recent head-to-head study in diet-induced obese rats (Sikiric 2024) compared the two compounds during semaglutide treatment. The authors measured lean mass retention, fat loss, and molecular markers of anabolism and catabolism over eight weeks. This article examines that study and places it in context with existing peptide research.
Study design and endpoints
Adult male Sprague-Dawley rats were fed a high-fat diet for 12 weeks to induce obesity, then switched to a 30% calorie-restricted diet while receiving semaglutide (0.05 mg/kg/day). Animals were randomised to four groups (n=12 each): vehicle control, IGF-1 LR3 (0.2 mg/kg every other day), Hexarelin (0.1 mg/kg twice daily), or a combination of both peptides at the same doses. Treatment lasted eight weeks.
Primary endpoints were change in lean body mass by dual-energy X-ray absorptiometry (DXA) and ex vivo muscle force in isolated soleus and extensor digitorum longus (EDL) muscles. Secondary endpoints included fat mass, fasting insulin, IGF-1 levels (total and free), and muscle mRNA expression of atrogin-1, MuRF-1, and myogenin.
What the data showed
Lean mass declined in all groups, but the loss was smallest with IGF-1 LR3. The vehicle group lost about 12% of starting lean mass. Hexarelin-treated rats lost roughly 9%, while IGF-1 LR3-treated rats lost only 5% (p<0.05 vs vehicle and Hexarelin). The combination group did not differ from IGF-1 LR3 alone.
Fat loss was similar across groups, suggesting the muscle-sparing effect was not simply due to blunted weight loss. Muscle force followed the same pattern: IGF-1 LR3 preserved approximately 85% of baseline tetanic force in EDL, compared to 70% in Hexarelin and 60% in vehicle (p<0.01).
Molecular markers told a consistent story. Atrogin-1 and MuRF-1 mRNA were suppressed more potently by IGF-1 LR3 than by Hexarelin. Myogenin expression, a marker of myogenic differentiation, was elevated only in the IGF-1 LR3 group. Total circulating IGF-1 rose more with Hexarelin (roughly 2.5-fold over baseline) than with IGF-1 LR3 (about 1.8-fold), but free IGF-1 was higher in the IGF-1 LR3 group, likely because the analogue binds less to IGF-binding proteins.
Authors' interpretation
Sikiric and colleagues concluded that IGF-1 LR3 provides superior muscle preservation during GLP-1-induced weight loss by directly activating muscle IGF-1 receptors, bypassing the GH/IGF-1 axis. They noted that Hexarelin's GH pulses raised total IGF-1 but did not translate into equivalent anabolic signalling, possibly because of concurrent increases in IGFBP-3 that limited free IGF-1 bioavailability. The authors speculated that the catabolic environment of severe caloric restriction may blunt the liver's IGF-1 response to GH, making a direct receptor agonist more reliable.
Annotated critique
Several points deserve scrutiny. First, the Hexarelin dosing regimen (twice-daily injections) attempted to mimic pulsatile GH secretion, but rats metabolise peptides faster than humans. The half-life of Hexarelin in rodents is in the neighbourhood of 20-30 minutes, so even twice-daily dosing may not sustain GH elevation adequately. A continuous infusion or a longer-acting secretagogue like CJC-1295 might have produced different results.
Second, the study used young adult rats with intact growth plates. IGF-1 LR3's effects in skeletally mature animals or humans might differ, particularly regarding bone turnover. A related review on IGF-1 LR3 and bone preservation during bulking highlights that IGF-1 LR3 can increase bone density in some contexts, but the relevance during weight loss is unclear.
Third, the semaglutide dose was relatively high, producing weight loss of roughly 20% over eight weeks. Whether the muscle-sparing advantage of IGF-1 LR3 holds at more moderate rates of weight loss (more typical of human use) is unknown. Finally, the study did not assess cardiac or metabolic safety beyond basic blood work. IGF-1 LR3's long half-life (20-30 hours in humans) raises concerns about sustained receptor activation and potential mitogenic effects, though no tumours were reported in this short study.
Implications and limits
This study provides mechanistic evidence that direct IGF-1 receptor agonism outperforms GH secretagogue-induced IGF-1 elevation for muscle preservation during caloric deficit. However, mechanism does not imply clinical effect. The data come from a single rodent study with a small sample size, and the endpoints, while relevant, are surrogate markers. No human trials have compared these peptides in the context of GLP-1 agonist use.
For researchers, the findings suggest that the GH/IGF-1 axis may be partially resistant during rapid weight loss, a phenomenon noted in earlier work on IGF-1 LR3 for muscle retention in caloric deficit. The study also aligns with observations that CJC-1295 and IGF-1 LR3 may have additive effects, though the combination group here did not show synergy.
Open questions remain: Would a longer-acting secretagogue like Tesamorelin produce results closer to IGF-1 LR3? Does the muscle-sparing effect persist after peptide discontinuation? And what are the long-term risks of IGF-1 LR3, particularly regarding cell proliferation? Until human data emerge, these peptides remain research compounds with uncertain benefit-risk profiles.
Common questions
Why didn't Hexarelin preserve more muscle if it raised IGF-1?
Hexarelin increased total IGF-1, but much of it was likely bound to IGFBP-3, reducing free, bioactive IGF-1. Additionally, GH pulses from Hexarelin are short-lived, and the liver's IGF-1 response may be blunted during severe caloric restriction. Direct IGF-1 receptor activation by IGF-1 LR3 bypasses these limitations.
Is IGF-1 LR3 safe for long-term use?
Long-term safety data in humans are absent. IGF-1 LR3's prolonged half-life and potent receptor activation raise theoretical concerns about cell proliferation and organ growth. Most rodent studies are short-term, and no chronic toxicity studies have been published. Caution is warranted.
Could combining IGF-1 LR3 with a GLP-1 agonist cause hypoglycaemia?
IGF-1 has insulin-like effects and can lower blood glucose. In this study,
This article discusses peptides as research compounds. It is not medical advice.